Journal: Journal of Clinical Investigation

Article Title: BVES regulates EMT in human corneal and colon cancer cells and is silenced via promoter methylation in human colorectal carcinoma

doi: 10.1172/jci44228

Figure Lengend Snippet: Figure 1 BVES expression is significantly downregulated, and it is mislocalized in human colon carcinoma. (A) A human BVES hydrolysis probe was used to perform qPCR on an Origene cDNA array (TissueScan Cancer Survey I). Ct values were normalized to β-actin and then presented as fold reduction from matched normal (N) (n = 3 per tissue type) and tumor (T) tissue (n = 9 per tissue type). ***P < 0.001, 2-tailed unpaired t test. (B) Analysis of the combined Moffit Cancer Center and Vanderbilt Medical Center colon tumor expression array data set (10, normal samples; 6, adenomas; 33, stage I; 76, stage 2; 82, stage 3; and 59, stage 4; for combined total of 250 CRC samples). For whisker plots, the bottom and top of the boxes are the 25th and 75th percentile, respectively (the lower and upper quartiles, respectively), and the band near the middle of the box is the 50th percentile (median). The whiskers extend to the most extreme data points, which are no more than 1.5 times the interquartile range from the box. *P = 0.04, ***P = 0.001, ****P = 0.0001. (C) Representative immunofluorescence images from normal colon or adenocarci- noma (original magnification, ×400) of H&E, BVES (green), ZO-1 (red), DAPI (blue), and merged images.

Article Snippet: BVES TaqMan qRT-PCR was performed on a multicancer tissue cDNA array (TissueScan Cancer Survey I, OriGene) according to the manufacturers protocol.

Techniques: Expressing, Whisker Assay, Immunofluorescence

Journal: Oncogene

Article Title: TACC3 deregulates the DNA damage response and confers sensitivity to radiation and PARP inhibition.

doi: 10.1038/onc.2014.105

Figure Lengend Snippet: Figure 5. TACC3 is elevated in a variety of human cancer types. (a) Transcript expression of TACC3 in eight solid human cancers, including breast, colon, kidney, liver, lung, ovary, prostate and thyroid cancers, was determined using TissueScan Cancer Survey qPCR array analysis. (b) Representative immunohistochemical staining of TACC3 on breast (normal breast tissues (n = 10) and breast cancer tissues (n = 100)) and lung (normal lung tissues (n = 10) and lung cancer tissues (n = 110)) cancer tissue microarrays (left panel). Quantitative analysis of breast and lung cancer tissue microarrays showed that the expression of TACC3 is higher in cancer tissues than in normal tissues (right panel). (c) Kaplan–Meier survival curves of breast (left panel) and lung (right panel) cancer patients based on TACC3 expression. (d) Graphs showing an inverse correlation between TACC3 and ATM mRNA levels in breast (Pearson’s r = −0.51341; Po0.01) and lung (Pearson’s r = −0.72401; Po0.0005) cancers based on TissueScan Cancer Survey qPCR array analysis. (e) A graph showing a positive correlation between TACC3 and γH2AX staining intensity scores of breast cancer tissue microarrays (n = 75) (Pearson’s r = 0.70052; Po0.05).

Article Snippet: TissueScan qPCR array The human TissueScan Cancer Survey cDNA array 96-I (OriGene Technologies Inc, Rockville, MD, USA) consisted of 96 tissues from eight solid tumors (breast, colon, kidney, liver, lung, ovary, prostate and thyroid). qPCR was performed in 96-well PCR array plates using the iCycler iQ5 realtime PCR detection system (Bio-Rad, Hercules, CA, USA) and an iQ SYBR Green supermix (Bio-Rad).

Techniques: Expressing, Immunohistochemical staining, Staining

Journal: PLoS ONE

Article Title: RecQL4 Helicase Amplification Is Involved in Human Breast Tumorigenesis

doi: 10.1371/journal.pone.0069600

Figure Lengend Snippet: (A) Western blot detection of RecQL4 protein level in HMEC, MCF-10F and five breast tumor cell lines. β-Actin was used to verify equal loading of proteins. (B) Analysis of RecQL4 expression by quantitative real time PCR in normal breast tissues and breast cancer specimens with different pathological grades. TissueScan breast cancer tissue qPCR array was purchased from Origene. RecQL4 expression detected in normal breast tissues was considered as 1. The data represent mean ± SD from three independent experiments.

Article Snippet: To verify whether or not RecQL4 expression is elevated in human breast tumor tissue samples, RecQL4 mRNA level was examined using TissueScan Human Breast cancer tissue qPCR array (Origene, Rockville, MD 20850).

Techniques: Western Blot, Expressing, Real-time Polymerase Chain Reaction

Journal: EJNMMI Research

Article Title: The La antigen is over-expressed in lung cancer and is a selective dead cancer cell target for radioimmunotherapy using the La-specific antibody APOMAB®

doi: 10.1186/2191-219X-4-2

Figure Lengend Snippet: Expression of La mRNA and protein in lung cancer. (A) The expression of La mRNA in normal compared to lung cancer samples was examined using the online database Oncomine. Two studies showed increased La mRNA expression in lung cancer samples compared to normal lung tissue. Data was taken from (I) Hou et al.’s study and (II) Landi et al . ’s study . Data are shown with 95% confidence intervals and circles representing outliers. LCLC, large cell lung cancer; SCC, squamous cell lung cancer; AC, adenocarcinoma. *** p < 0.001. (B) Photomicrographs of DAB4 staining pattern in sections of resected human lung tumours. TissueFocus Cancer Survery Tissue Microarray (Origene) was examined via immunohistochemistry for DAB4 expression. (I) Poorly differentiated squamous cell carcinoma of bronchus (case No. 0000019032): tumour cells (T); hypocellular stroma (S) with variable DAB4 expression (evident as brown staining) of normal cells including endothelial cells and other stromal cells (arrowheads). (II) Adenosquamous carcinoma (case No. 0000016518): predominantly basaloid squamous cell carcinoma (T) with prominent DAB4-stained nucleoli (arrowheads); desmoplastic stromal reaction (S) with both DAB4-stained and unstained nuclei of stromal cells (arrow). (III) Poorly differentiated adenocarcinoma (case No. 0000008378): acinar structures (A) are evidently interweaved with a hypercellular stroma (S). Some malignant cells were not stained with DAB4 (arrowheads). (IV) Poorly differentiated lung adenocarcinoma (case No. 0000016267): the high-grade malignant cells (T) are vacuolated and have weak non-specific cytoplasmic staining with DAB4 (arrowheads); a desmoplastic stromal reaction (S) with DAB4-stained lymphoplasmacytic infiltrates (arrows). (V and VI) Normal lung tissue (case No. 0000000144 and 0000006853) showed reduced, predominantly nuclear DAB4 staining. All sections are shown at × 20 magnification, and scale bars are indicated.

Article Snippet: A TissueFocus Cancer Survey Tissue Microarray (Origene, Rockville, MD, USA) was dewaxed and endogenous peroxidase activity was blocked with 0.5% hydrogen peroxide in methanol.

Techniques: Expressing, Staining, Microarray, Immunohistochemistry

Journal: Cancers

Article Title: Targeting and Sensitization of Breast Cancer Cells to Killing with a Novel Interleukin-13 Receptor α2-Specific Hybrid Cytolytic Peptide.

doi: 10.3390/cancers15102772

Figure Lengend Snippet: Figure 1. Expression of IL-13Rα2 in breast cancer tissue. (a) RT-PCR analysis of IL-13Rα2 mRNA expression in cDNA array samples (TissueScan™, Origene) derived from breast cancer (number of samples (n = 60)) and non-malignant (n = 7) tissue. Shown is the fold-change relative to mean expression in non-malignant samples (mean fold-change, cancer versus non-malignant; *** p ≤0.001). (b) Stratification analysis of IL-13Rα2 mRNA expression data comparing TNBC-type (n = 19) versus non-TNBC (n = 41) tumors (mean fold-change, TNBC versus non-TNBC, *** p ≤0.001). (c) Im- munohistochemical analysis of IL-13Rα2 protein expression in breast cancer tissue array samples (US Biomax, BR1009). Shown images (at 40× magnification) are representative examples of specific staining with an anti-IL-13Rα2 antibody (sc-134363) versus a mouse IgG2a isotype control: (left panel), non-malignant tissue; (middle panel) non-TNBC tumor (ER+, stage IIa); (right panel) TNBC tumor (stage IIb). (Right Figure), scoring analysis of anti-IL-13Rα2 reactivity in non-malignant (n = 9), non-TNBC (n = 8), and TNBC (n = 21) tissue array sections (mean score, TNBC versus non-malignant, *** p ≤0.001).

Article Snippet: Expression of IL-13Rα2 in breast cancer tissue. (a) RT-PCR analysis of IL-13Rα2 mRNA expression in cDNA array samples (TissueScanTM, Origene) derived from breast cancer (number of samples (n = 60)) and non-malignant (n = 7) tissue.

Techniques: Expressing, Reverse Transcription Polymerase Chain Reaction, Derivative Assay, Staining, Control